Dynamic risk factors associated with non‐severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly 与每日一次使用甘精胰岛素或者每周一次使用艾塞那肽治疗的患者出现非严重低血糖相关的动态危险因素

Paul, Sanjoy K.; Maggs, David; Klein, Kerenaftali; Best, Jennie H.

doi:10.1111/1753-0407.12208

Cited by 9 publications

(8 citation statements)

References 27 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported a 14% significantly reduced risk of hypoglycemia associated with higher levels of FPG during 52 weeks of follow‐up in both EQW‐ and IG‐treated patients . Higher visit‐based postprandial glucose levels were reported to be associated with an 8% reduced risk of hypoglycemia in patients treated with EQW ( P = 0.010), but not in patients treated with IG . In the present study, the average postprandial glucose levels from SMBG profiles were not significantly higher in patients who experienced hypoglycemia (EQW, 0.37 mmol/L [ P = 0.08]; IG, 0.21 mmol/L [ P = 0.45]).…”

Section: Discussioncontrasting

confidence: 52%

“…Paul et al . reported a 14% significantly reduced risk of hypoglycemia associated with higher levels of FPG during 52 weeks of follow‐up in both EQW‐ and IG‐treated patients . Higher visit‐based postprandial glucose levels were reported to be associated with an 8% reduced risk of hypoglycemia in patients treated with EQW ( P = 0.010), but not in patients treated with IG .…”

Section: Discussionmentioning

confidence: 99%

“…Patients experiencing hypoglycemia had, on average, similar lower levels of average preprandial level (EQW, 0.64 mmol/L; IG, 0.66 mmol/L). Paul et al . reported a 14% significantly reduced risk of hypoglycemia associated with higher levels of FPG during 52 weeks of follow‐up in both EQW‐ and IG‐treated patients .…”

Section: Discussionmentioning

confidence: 99%

“…Hypoglycemia has been well recognized as an adverse consequence of treatment with some antidiabetes therapies in patients with type 2 diabetes mellitus (T2DM) . Several clinical and epidemiological studies have demonstrated hypoglycemia as a common problem in insulin‐treated patients with T2DM, and hypoglycemia has been associated with the increased risk of cardiovascular events . Hypoglycemia in T2DM is also associated with the need for hospital care, incumbent cost, and death …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of trajectories of self‐monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

Paul

Agbeve

Maggs

et al. 2015

Journal of Diabetes

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of trajectories of self‐monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

Paul

Agbeve

Maggs

et al. 2015

Journal of Diabetes

Self Cite

View full text Add to dashboard Cite

show abstract

“…In clinical trials, treatment with exenatide once a week assisted more patients in reaching the majority of ADA-recommended therapeutic goals than treatments with other drugs, such as sitagliptin, pioglitazone, or insulin glargine [6]. However, the residual adverse effect of sulphonylurea was also higher in patients who were treated with exenatide once a week [7]. Compared to conventional treatments, GLP-1RAs not only have an advantage in lowering blood sugar, but also have other benefits.…”

Section: Introductionmentioning

confidence: 99%

Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway

Zhan

Tan

Wang

et al. 2014

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundArterial calcification is an important pathological change of diabetic vascular complication. Osteoblastic differentiation of vascular smooth muscle cells (VSMCs) plays an important cytopathologic role in arterial calcification. The glucagon-like peptide-1 receptor agonists (GLP-1RA), a novel type of antidiabetic drugs, exert cardioprotective effects through the GLP-1 receptor (GLP-1R). However, the question of whether or not GLP-1RA regulates osteoblastic differentiation and calcification of VSMCs has not been answered, and the associated molecular mechanisms have not been examined.MethodsCalcifying VSMCs (CVSMCs) were isolated from cultured human arterial smooth muscle cells through limiting dilution and cloning. The extent of matrix mineralization was measured by Alizarin Red S staining. Protein expression and phosphorylation were detected by Western blot. Gene expression of receptor activator of nuclear factor-κB ligand (RANKL) was silenced by small interference RNA (siRNA).ResultsExenatide, an agonist of GLP-1 receptor, attenuated β-glycerol phosphate (β-GP) induced osteoblastic differentiation and calcification of human CVSMCs in a dose- and time-dependent manner. RANKL siRNA also inhibited osteoblastic differentiation and calcification. Exenatide decreased the expression of RANKL in a dose-dependent manner. 1,25 vitD3 (an activator of RANKL) upregulated, whereas BAY11-7082 (an inhibitor of NF-κB) downregulated RANKL, alkaline phosphatase (ALP), osteocalcin (OC), and core binding factor α1 (Runx2) protein levels and reduced mineralization in human CVSMCs. Exenatide decreased p-NF-κB and increased p-AMPKα levels in human CVSMCs 48 h after treatment. Significant decrease in p-NF-κB (p-Ser276, p-Ser536) level was observed in cells treated with exenatide or exenatide + BAY11-7082.ConclusionGLP-1RA exenatide can inhibit human VSMCs calcification through NF-κB/RANKL signaling.

show abstract

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

2017

View full text Add to dashboard Cite

IntroductionExenatide once weekly (ExeOW, Bydureon®, Astra Zeneca), a drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, is the first agent approved for treatment of type 2 diabetes (T2D) that can be administered on a weekly basis.MethodsData concerning treatment of T2D with ExeOW are reviewed with special reference to its long-term efficacy, tolerability, and safety. Relevant literature was identified through the PubMed database from inception to January 2015.ResultsIn randomized clinical trials ExeOW, as add-on to oral antidiabetics, achieved significantly improved glycemic control compared to maximum recommended doses of exenatide twice daily, sitagliptin, pioglitazone, and insulin glargine, as measured by HbA1c. In drug-naïve patients ExeOW was superior to sitagliptin and non-inferior to metformin, whereas non-inferiority to pioglitazone and liraglutide was not proven. In different trials reductions in HbA1c ranged from −1.1% to −2.0%. ExeOW therapy over 6 months was also associated with a mean weight loss of −2 to −4 kg, improved systolic blood pressure and lipid profile, and no hypoglycemia unless associated to sulfonylurea. ExeOW long-term therapy up to 3–6 years allowed persistent glycemic control (HbA1c −1.6%), sustained decreases in blood pressure (−2 mmHg), and improvements of lipid profile. ExeOW tolerability was comparable to that of the other GLP-1 receptor agonists, with better gastrointestinal tolerability when direct comparison was done (namely liraglutide and exenatide BID), but higher incidence of injection site reactions and few treatment discontinuations mainly due to gastrointestinal events.ConclusionExeOW is a well-tolerated and convenient option for long-term treatment of T2D allowing significant and persistent glycemic control with moderate weight loss and low risk of hypoglycemia unless associated with sulfonylureas.

show abstract

Dynamic risk factors associated with non‐severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly 与每日一次使用甘精胰岛素或者每周一次使用艾塞那肽治疗的患者出现非严重低血糖相关的动态危险因素

Abstract: This study revealed differential effects of tight glycemic control and itsinteraction with treatment-induced changes in BMI on hypoglycemia risk its interaction in patients treated with EQW and IG. The residual adverse effect of sulfonylurea was higher in EQW-treated patients.

Cited by 9 publications

References 27 publications

Comparison of trajectories of self‐monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

Comparison of trajectories of self‐monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

Contact Info

Product

Resources

About